reference/12592443

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12592443

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase I\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	594
issn	1058-4838 1537-6591
issueIdentifier	4
pageRange	591-594
publicationName	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
startingPage	591
bibliographicCitation	Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis. 2004 Aug 15;39(4):591–4. doi: 10.1086/422452. PMID: 15356829.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d0dec8bf968465e862d2a0658563a64 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9757eb4f41ef8fba04940d6a8c61f905 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b4e3bde119f308fb4d6ce58c85a0bc99 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47d0da3ecbadde5ecfada609f8af1a71 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_96717ad58cadab1f45c8ed8fca6e4683 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24d69880a092ec3cc5ab855673667de5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4661469911d3308158a6b5792fb3cb3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e35cdc1db844c5c46e1a40a5698c071b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6fad33c4b114a074e36ea911236a50b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3c511058b5d6cf8b11b8ad925440f7e9
date	2004-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/15356829 https://doi.org/10.1086/422452
isPartOf	https://portal.issn.org/resource/ISSN/1058-4838 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1135 https://portal.issn.org/resource/ISSN/1537-6591
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients
discusses	http://id.nlm.nih.gov/mesh/M0028918 http://id.nlm.nih.gov/mesh/M0003327 http://id.nlm.nih.gov/mesh/M0008898 http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0250495
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D019438Q000008 http://id.nlm.nih.gov/mesh/D013449Q000627 http://id.nlm.nih.gov/mesh/D019438Q000493 http://id.nlm.nih.gov/mesh/D013449Q000493 http://id.nlm.nih.gov/mesh/D015658Q000188 http://id.nlm.nih.gov/mesh/D023241Q000009 http://id.nlm.nih.gov/mesh/D023241Q000379
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D013449Q000009 http://id.nlm.nih.gov/mesh/D013449Q000008 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D005663 http://id.nlm.nih.gov/mesh/D015658Q000097 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D002219 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000328
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441300 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60825 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID392622 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65016

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128575040 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128681033 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128324017 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129815097

Total number of triples: 61.